PL2303330T5 - Kompozycje farmaceutyczne do leczenia choroby Parkinsona - Google Patents
Kompozycje farmaceutyczne do leczenia choroby ParkinsonaInfo
- Publication number
- PL2303330T5 PL2303330T5 PL09758025T PL09758025T PL2303330T5 PL 2303330 T5 PL2303330 T5 PL 2303330T5 PL 09758025 T PL09758025 T PL 09758025T PL 09758025 T PL09758025 T PL 09758025T PL 2303330 T5 PL2303330 T5 PL 2303330T5
- Authority
- PL
- Poland
- Prior art keywords
- parkinson
- disease
- treatment
- pharmaceutical compositions
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5932608P | 2008-06-06 | 2008-06-06 | |
EP09758025.2A EP2303330B2 (en) | 2008-06-06 | 2009-06-07 | Pharmaceutical compositions for treatment of parkinson's disease |
PCT/IL2009/000567 WO2009147681A1 (en) | 2008-06-06 | 2009-06-07 | Pharmaceutical compositions for treatment of parkinson's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
PL2303330T3 PL2303330T3 (pl) | 2018-04-30 |
PL2303330T5 true PL2303330T5 (pl) | 2021-10-25 |
Family
ID=41051156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09758025T PL2303330T5 (pl) | 2008-06-06 | 2009-06-07 | Kompozycje farmaceutyczne do leczenia choroby Parkinsona |
Country Status (22)
Country | Link |
---|---|
US (2) | US8969417B2 (pl) |
EP (1) | EP2303330B2 (pl) |
JP (1) | JP5648216B2 (pl) |
KR (1) | KR101613749B1 (pl) |
CN (1) | CN102105169B (pl) |
AU (1) | AU2009254730B2 (pl) |
BR (1) | BRPI0914902B8 (pl) |
CA (1) | CA2726833C (pl) |
CL (1) | CL2010001358A1 (pl) |
CY (1) | CY1119865T1 (pl) |
DK (1) | DK2303330T4 (pl) |
ES (1) | ES2659394T5 (pl) |
HU (1) | HUE037974T2 (pl) |
LT (1) | LT2303330T (pl) |
MX (1) | MX2010013393A (pl) |
NO (1) | NO2303330T3 (pl) |
NZ (1) | NZ590291A (pl) |
PL (1) | PL2303330T5 (pl) |
PT (1) | PT2303330T (pl) |
RU (1) | RU2540470C9 (pl) |
WO (1) | WO2009147681A1 (pl) |
ZA (1) | ZA201100034B (pl) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG183150A1 (en) | 2010-02-03 | 2012-09-27 | Pharma Two B Ltd | Extended release formulations of rasagiline and uses thereof |
TW201304822A (zh) * | 2010-11-15 | 2013-02-01 | Vectura Ltd | 組成物及用途 |
US9504657B2 (en) * | 2012-01-12 | 2016-11-29 | Pharmatwob Ltd. | Fixed dose combination therapy of Parkinson's disease |
JP6243351B2 (ja) * | 2012-01-12 | 2017-12-06 | ファーマ ツゥ ビー リミテッド | パーキンソン病の固定投与量薬剤組合せ治療 |
WO2013168032A1 (en) * | 2012-05-07 | 2013-11-14 | Micro Labs Limited | Pharmaceutical compositions comprising rasagiline |
KR101320945B1 (ko) * | 2012-07-03 | 2013-10-23 | 주식회사파마킹 | 에스-알릴-엘-시스테인을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 및 이를 포함하는 의약제제 |
BR112015006093A2 (pt) * | 2012-09-27 | 2017-07-04 | Teva Pharma | combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington |
WO2014139161A1 (en) | 2013-03-15 | 2014-09-18 | Techfields Pharma Co., Ltd. | Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases |
EP2808023A1 (en) * | 2013-05-30 | 2014-12-03 | Université Pierre et Marie Curie (Paris 6) | New drug for the treatment and/or prevention of depressive disorders |
CN104473942A (zh) * | 2014-12-12 | 2015-04-01 | 青岛大学 | 一种抗帕金森氏病的药物组合物 |
ES2869981T3 (es) | 2015-05-26 | 2021-10-26 | Technophage Investig E Desenvolvimento Em Biotecnologia Sa | Composiciones para su uso en el tratamiento de la enfermedad de parkinson y trastornos relacionados |
WO2017070293A1 (en) * | 2015-10-20 | 2017-04-27 | Ironwood Pharmaceuticals, Inc. | Phosphodiesterase 9 inhibitor and levodopa therapy |
US20170143681A1 (en) * | 2015-11-02 | 2017-05-25 | Apkarian Technologies Llc | Methods and compositions for treating pain |
WO2018116293A1 (en) * | 2016-12-22 | 2018-06-28 | Rvx Therapeutics Ltd. | Low dose drug combinations for use in preventing and treating neuronal damage |
US11253594B2 (en) * | 2017-07-07 | 2022-02-22 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Drug combinations for protecting against neuronal cell death |
JP6596483B2 (ja) * | 2017-12-28 | 2019-10-23 | テックフィールズ ファーマ カンパニー リミテッド | パ−キンソン病治療用の新規高透過薬物及びその組成物 |
WO2020084168A1 (en) * | 2018-10-26 | 2020-04-30 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Tetracycline compound for treating drug-induced dyskinesia |
WO2020227646A1 (en) * | 2019-05-09 | 2020-11-12 | Apkarian Technologies Llc | Methods and compositions for treating pain |
US20230028539A1 (en) | 2019-12-06 | 2023-01-26 | Shanghai Pharmaceuticals Holding Co., Ltd. | Pharmaceutical composition, complementary kit and application thereof |
WO2022020621A1 (en) | 2020-07-24 | 2022-01-27 | XWPharma Ltd. | Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative |
JP2023541048A (ja) * | 2020-09-10 | 2023-09-27 | プロシーナ バイオサイエンシーズ リミテッド | パーキンソン病の処置 |
JP2023544420A (ja) | 2020-10-05 | 2023-10-23 | エックスダブリューファーマ リミテッド | ガンマ-ヒドロキシ酪酸誘導体の調節放出組成物 |
CN114762684B (zh) * | 2021-01-14 | 2023-11-21 | 华益泰康药业股份有限公司 | 一种治疗帕金森的缓释胶囊及其制备方法 |
EP4308086A1 (en) | 2021-03-19 | 2024-01-24 | XWPharma Ltd. | Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3764144D1 (de) * | 1986-04-16 | 1990-09-13 | Asta Pharma Ag | Synergistische kombination von amantadin und selegilin. |
US5221536A (en) * | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5190763A (en) * | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
EP0828513B1 (en) * | 1995-05-26 | 2004-01-21 | Pfizer Inc. | Combinations for the treatment of parkinsonism containing selective nmda antagonists |
WO2001078711A2 (en) | 2000-04-19 | 2001-10-25 | Lilly Icos, Llc. | Pde-v inhibitors for treatment of parkinson's disease |
US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
FR2857594B1 (fr) * | 2003-07-17 | 2005-09-16 | Servier Lab | Composition pharmaceutique pour l'administration par voie nasale de piribedil |
CA2555399A1 (en) | 2004-02-20 | 2005-09-01 | Novartis Ag | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
EP1901721A1 (en) | 2005-06-23 | 2008-03-26 | Spherics, Inc. | Delayed release or extended-delayed release dosage forms of pramipexole |
WO2007048034A2 (en) | 2005-10-21 | 2007-04-26 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Use of androgens for the treatment of parkinson' s disease |
CA2635313C (en) * | 2005-12-29 | 2013-12-31 | Osmotica Corp. | Triple combination release multi-layered tablet |
SI1991522T1 (sl) | 2006-02-17 | 2016-10-28 | Ratiopharm Gmbh | Devterirani derivati kateholaminov in zdravila, ki omenjene spojine vsebujejo |
EP2007369A4 (en) | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
JP2009537565A (ja) | 2006-05-16 | 2009-10-29 | ノップ ニューロサイエンシーズ、インク. | R(+)およびs(−)プラミペキソール組成とそれを利用する方法 |
US20090298878A1 (en) | 2006-07-14 | 2009-12-03 | Akira Matsumura | Oxime compounds and the use thereof |
US7531572B2 (en) | 2006-07-28 | 2009-05-12 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use |
ATE510538T1 (de) | 2006-08-11 | 2011-06-15 | Univ Johns Hopkins | Zusammensetzungen und verfahren für nervenschutz |
US20100093706A1 (en) | 2006-08-21 | 2010-04-15 | Prexa Pharmaceuticals, Inc. | Multimediator transporter inhibitors for use in treatment of central nervous system disorders |
US7622495B2 (en) | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
NZ575939A (en) | 2006-11-01 | 2011-09-30 | Purdue Pharma Lp | Phenylpropionamide compounds and the use thereof |
EP2150239A1 (en) * | 2007-04-24 | 2010-02-10 | Boehringer Ingelheim International GmbH | Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
-
2009
- 2009-06-07 DK DK09758025.2T patent/DK2303330T4/da active
- 2009-06-07 EP EP09758025.2A patent/EP2303330B2/en active Active
- 2009-06-07 ES ES09758025T patent/ES2659394T5/es active Active
- 2009-06-07 AU AU2009254730A patent/AU2009254730B2/en active Active
- 2009-06-07 BR BRPI0914902A patent/BRPI0914902B8/pt active IP Right Grant
- 2009-06-07 HU HUE09758025A patent/HUE037974T2/hu unknown
- 2009-06-07 LT LTEP09758025.2T patent/LT2303330T/lt unknown
- 2009-06-07 KR KR1020117000189A patent/KR101613749B1/ko active IP Right Grant
- 2009-06-07 CN CN200980129250.2A patent/CN102105169B/zh active Active
- 2009-06-07 JP JP2011512269A patent/JP5648216B2/ja active Active
- 2009-06-07 MX MX2010013393A patent/MX2010013393A/es active IP Right Grant
- 2009-06-07 RU RU2010154716/15A patent/RU2540470C9/ru active
- 2009-06-07 WO PCT/IL2009/000567 patent/WO2009147681A1/en active Application Filing
- 2009-06-07 CA CA2726833A patent/CA2726833C/en active Active
- 2009-06-07 PL PL09758025T patent/PL2303330T5/pl unknown
- 2009-06-07 PT PT97580252T patent/PT2303330T/pt unknown
- 2009-06-07 US US12/996,455 patent/US8969417B2/en active Active
- 2009-06-07 NZ NZ590291A patent/NZ590291A/xx unknown
- 2009-06-07 NO NO09758025A patent/NO2303330T3/no unknown
-
2010
- 2010-12-06 CL CL2010001358A patent/CL2010001358A1/es unknown
-
2011
- 2011-01-03 ZA ZA2011/00034A patent/ZA201100034B/en unknown
-
2015
- 2015-01-22 US US14/602,518 patent/US9259418B2/en not_active Expired - Fee Related
-
2018
- 2018-01-31 CY CY20181100112T patent/CY1119865T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201100034B (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
EP2151435A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
EP2382176A4 (en) | USE OF CURCUMIN ANALOGUES CONTAINING NITROGEN FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
ZA201002751B (en) | Compositions for treating parkinson's disease | |
HK1163500A1 (en) | Pharmaceutical composition for the treatment of heart diseases | |
EP2312945A4 (en) | PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER | |
IL230335A (en) | A drug used to treat cartilage disease | |
IL208350A0 (en) | Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease | |
PL2197883T3 (pl) | Pochodna katecholaminy użyteczna do leczenia choroby Parkinsona | |
EP2312946A4 (en) | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
EP2268647A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE IDENTIFICATION AND TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES | |
EP2306824A4 (en) | IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER | |
ZA200805761B (en) | Pharmaceutical composition for the treatment of nail disease | |
EP2320939A4 (en) | TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE | |
EP2213303A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT | |
EP2210621A4 (en) | COMPOSITION FOR THE TREATMENT OF JOINT DISEASES | |
ZA201009072B (en) | Pharmaceutical composition for the treatment of premature ejaculation | |
WO2010085799A9 (en) | Compositions and method for the treatment of parkinson's disease | |
IL217149A0 (en) | Compositions and methods for treating parkinson's disease | |
EP2349308A4 (en) | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
EP2413696A4 (en) | COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
EP2517698A4 (en) | ACTIVE AGENT FOR THE TREATMENT OF MORBUS PARKINSON | |
EP2517704A4 (en) | PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE AND METHOD OF MAKING SAME | |
PT2344166E (pt) | Composição farmacêutica para o tratamento da irritação gastrointestinal | |
EP2305629A4 (en) | THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE |